Fisetin vs FOXO4-DRI

Both are researched as senolytics that clear senescent cells. Fisetin is a dietary flavonoid in human trials; FOXO4-DRI is a synthetic peptide that disrupts FOXO4–p53 binding, tested in mice.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Fisetin

A plant flavonoid (strawberries, apples) identified as one of the most potent natural senolytics in screening studies.

BEST STUDIED FOR

Mitochondrial & longevity

Read the cited profile →

🧪

FOXO4-DRI

A D-retro-inverso peptide designed to disrupt the FOXO4–p53 interaction that keeps senescent cells alive — a senolytic research tool.

BEST STUDIED FOR

Mitochondrial & longevity

Read the cited profile →

SIDE BY SIDE

	Fisetin	FOXO4-DRI
The key difference	Plant flavonoid senolytic	Engineered peptide senolytic
Class	Mitochondrial & longevity	Mitochondrial & longevity
Mechanism	Fisetin selectively reduces senescent cells and their inflammatory secretions (SASP) in mice; intermittent dosing improved arterial and muscle function in aged animals.	In senescent cells, FOXO4 binds p53 and holds it in the nucleus, preventing apoptosis.
Status	Preclinical evidence is strong; human senolytic trials are in progress. Sold as a supplement.	Preclinical (aged and chemotoxicity mouse models, Leydig and endothelial senescence, keloid fibroblasts). No human trials published.
Reported safety signals	Low toxicity in animal studies; human data are limited.	No human safety data; a 2023 study found eliminating senescent cells can worsen pulmonary hypertension in animal models, a caution for senolytics broadly.
A key study	Fisetin reduced senescence markers and extended health and lifespan in mice. (EBioMedicine 2018, PMID 30279143)	The discovery study: a FOXO4 peptide induced apoptosis of senescent cells and restored tissue homeostasis in mice. (Cell 2017, PMID 28340339)

WHEN TO RESEARCH WHICH

Fisetin is closer to the clinic; FOXO4-DRI is a mechanism-specific research tool. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Fisetin] Fisetin is a senotherapeutic that extends health and lifespan — EBioMedicine 2018. PMID 30279143
[Fisetin] Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence — Aging Cell 2024. PMID 38062873
[Fisetin] Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches — Aging Cell 2025. PMID 40437670
[FOXO4-DRI] Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging — Cell 2017. PMID 28340339
[FOXO4-DRI] The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI — Nat Commun 2025. PMID 40593617
[FOXO4-DRI] FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice — Aging (Albany NY) 2020. PMID 31959736

FREQUENTLY ASKED

What is the difference between Fisetin and FOXO4-DRI?

Both are researched as senolytics that clear senescent cells. Fisetin is a dietary flavonoid in human trials; FOXO4-DRI is a synthetic peptide that disrupts FOXO4–p53 binding, tested in mice.

What is the regulatory status of Fisetin and FOXO4-DRI?

Fisetin: Preclinical evidence is strong; human senolytic trials are in progress. Sold as a supplement. FOXO4-DRI: Preclinical (aged and chemotoxicity mouse models, Leydig and endothelial senescence, keloid fibroblasts). No human trials published.

What safety signals have been reported?

Fisetin: Low toxicity in animal studies; human data are limited. FOXO4-DRI: No human safety data; a 2023 study found eliminating senescent cells can worsen pulmonary hypertension in animal models, a caution for senolytics broadly.

Which studies is this comparison based on?

For Fisetin: “Fisetin is a senotherapeutic that extends health and lifespan” (PMID 30279143); “Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence” (PMID 38062873); “Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches” (PMID 40437670). For FOXO4-DRI: “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging” (PMID 28340339); “The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI” (PMID 40593617); “FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice” (PMID 31959736).